Arcturus Therapeutics(ARCT) - 2025 Q4 - Annual Results

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress ARCT-032 (CF) Phase 2 third cohort (28 days, 15 mg) generally safe and well tolerated ARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026 Cash runway extended into Q2 2028 Investor conference call at 4:30 p.m. ET today SAN DIEGO--(BUSINESS WIRE) --Mar. 3, 2026--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company ...